droxidopa (northera) Report issue

Small molecule Orphan Drug FDA Approved FDA First in Class Fast Track FDA Accelerated Approval FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Droxidopa (Northera, Chelsea Therapeutics) is a synthetic catecholamino acid precursor of norepinephrine indicated for the treatment of orthostatic dizziness or lightheadedness in adult patients with symptomatic neurogenic orthostatic hypotension (NOH) caused by primary autonomic failure, dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Droxidopa was approved as oral therapy in February 2014 under the FDA’s accelerated approval program. Droxidopa is directly metabolized to norepinephrine by dopadecarboxylase. The specific mechanism of action of the drug is not known completely, but it is supposed to exert the pharmacological effects through norepinephrine and not through the parent molecule or other metabolites. It increases blood flow to the brain by stimulating peripheral arterial and venous vasoconstriction.   NCATS

Chemistry

  • SMILES: N[C@@H]([C@H](O)C1=CC=C(O)C(O)=C1)C(O)=O
  • InChIKey: QXWYKJLNLSIPIN-JGVFFNPUSA-N
  • Mol. Mass: 213.1873
  • ALogP: -0.46
  • ChEMBL Molecule:
    droxidopa  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$1.0578 - $85.1717
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

dihydroxyphenylserine | dops | droxidopa | l-dihydroxyphenylserine | l-dops | l-threo | l-threo-3,4-dihydroxyphenylserine | l-threo-dihydroxyphenylserine | l-threo dops | northera | threo-dopaserine

Organizations (57)

Research & Development (38)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (21)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (31)

Approved Indications (2)


 

Hypotension, Orthostatic

Multiple System Atrophy

Experimental Indications - Clinical Trial Phases 1-4 (31)


 

Accidental Falls (Phase 2)

Atrophy (Phase 3)

Attention Deficit Disorder with Hyperactivity (Phase 2)

Autonomic Nervous System Diseases (Phase 3)

Cognition Disorders (Phase 2)

Diabetes Mellitus (Phase 3)

Dopamine beta-Hydroxylase (Phase 3)

Fatigue (Phase 4)

Fatigue Syndrome, Chronic (Phase 2)

Fibromyalgia (Phase 2)

Gait (Phase 2)

Gait Disorders, Neurologic (Phase 1/Phase 2)

Heart (Phase 1)

Hereditary Sensory and Autonomic Neuropathies (Phase 2)

Hypotension (Phase 4)

Hypotension, Orthostatic ()

Kidney Diseases (Phase 1)

Kidney Failure, Chronic (Phase 1)

Menkes Kinky Hair Syndrome (Phase 1/Phase 2)

Multiple System Atrophy (Phase 3)

Occipital Lobe (Phase 1/Phase 2)

Orthostatic Intolerance (Phase 3)

Parkinson Disease (Phase 4)

Parkinsonian Disorders (Phase 4)

Postural Orthostatic Tachycardia Syndrome (Phase 1/Phase 2)

Pure Autonomic Failure (Phase 3)

Spinal Cord Injuries (Phase 4)

Supranuclear Palsy, Progressive (Phase 2)

Syncope (Phase 2)

Tachycardia (Phase 2)

Vagus Nerve (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 38
  • # of Trial Organizations: 38

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue